Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade F 40.44 0.20% 0.08
FGEN closed up 0.2 percent on Friday, November 16, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical FGEN trend table...

Date Alert Name Type % Chg
Nov 16 Hammer Candlestick Bullish 0.00%
Nov 16 NR7 Range Contraction 0.00%
Nov 16 Multiple of Ten Bullish Other 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 MACD Bullish Signal Line Cross Bullish 0.20%
Nov 15 Earnings Movers Other 0.20%
Nov 15 Multiple of Ten Bullish Other 0.20%
Nov 15 Wide Bands Range Expansion 0.20%
Nov 15 Oversold Stochastic Weakness 0.20%

Older signals for FGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Is FGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 68.55
52 Week Low 38.52
Average Volume 611,439
200-Day Moving Average 54.5786
50-Day Moving Average 51.313
20-Day Moving Average 43.429
10-Day Moving Average 41.394
Average True Range 2.7616
ADX 38.42
+DI 9.8805
-DI 26.0653
Chandelier Exit (Long, 3 ATRs ) 47.6252
Chandelier Exit (Short, 3 ATRs ) 46.8048
Upper Bollinger Band 50.1314
Lower Bollinger Band 36.7266
Percent B (%b) 0.28
BandWidth 30.866011
MACD Line -3.2577
MACD Signal Line -3.3628
MACD Histogram 0.1051
Fundamentals Value
Market Cap 2.88 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -21.06
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.25
Resistance 3 (R3) 42.98 41.79 42.78
Resistance 2 (R2) 41.79 41.07 41.92 42.62
Resistance 1 (R1) 41.11 40.63 41.45 41.38 42.47
Pivot Point 39.92 39.92 40.09 40.05 39.92
Support 1 (S1) 39.24 39.20 39.58 39.51 38.41
Support 2 (S2) 38.05 38.76 38.18 38.26
Support 3 (S3) 37.37 38.05 38.10
Support 4 (S4) 37.64